Neuroprotective Effects of Lutein in the Retina by Ozawa, Yoko et al.
  Current Pharmaceutical Design, 2012, 18, 51-56  51 
 1873-4286 /12 $58.00+.00   © 2012 Bentham Science Publishers 
Neuroprotective Effects of Lutein in the Retina 
Yoko Ozawa
1,2*, Mariko Sasaki
1,2, Noriko Takahashi
1,2, Mamoru Kamoshita
1,2, Seiji Miyake
1 and Kazuo 
Tsubota
2 
1Laboratory of Retinal Cell Biology, 
2Department of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shin-
juku-ku, Tokyo 160-8582, Japan  
Abstract: Although a large variety of pharmaceutical therapies for treating disease have been developed in recent years, there has been 
little progress in disease prevention. In particular, the protection of neural tissue is essential, because it is hardly regenerated. The use of 
nutraceuticals for maintaining the health has been supported by several clinical studies, including cross-sectional and interventional stud-
ies for age-related macular disease. However, mechanistic evidence for their effects at the molecular level has been very limited. In this 
review, we focus on lutein, which is a xanthophyll type of carotenoid. Lutein is not synthesized in mammals, and must be obtained from 
the diet. It is delivered to the retina, and in humans, it is concentrated in the macula. Here, we describe the neuroprotective effects of lu-
tein and their underlying molecular mechanisms in animal models of vision-threatening diseases, such as innate retinal inflammation, 
diabetic retinopathy, and light-induced retinal degeneration. In lutein-treated mouse ocular disease models, oxidative stress in the retina is 
reduced, and its downstream pathological signals are inhibited. Furthermore, degradation of the functional proteins, rhodopsin (a visual 
substance) and synaptophysin (a synaptic vesicle protein also influenced in other neurodegenerative diseases such as Alzheimer’s disease 
and Parkinson’s disease), the depletion of brain-derived neurotrophic factor (BDNF), and DNA damage are prevented by lutein, which 
preserves visual function. We discuss the possibility of using lutein, an antioxidant, as a neuroprotective treatment for humans.  
Keywords: Oxidative stress, neuroprotection, lutein, retina, visual function, protein degradation, DNA damage, synaptophysin, BDNF, ubiq-
uitin proteasome system. 
INTRODUCTION 
  Recent progress has led to the development of various kinds of 
chemically synthesized drugs. However, many therapeutic com-
pounds have been also found in nature. Here, we focus on lutein, a 
phytochemical categorized as a carotenoid, and describe animal 
data that may support its future use as a neuroprotective treatment. 
1. GENERAL INFORMATION ABOUT LUTEIN  
  Phytochemicals are plant-derived compounds that are not es-
sential nutrients for sustaining life. Because they often have pig-
ments, fragrance, or a bitter taste, they have been thought to play a 
protective role against external threats, such as ultraviolet light, 
pathogens, and creatures that eat plants. The carotenoid group in-
cludes phytochemicals with the basic structure C40H56. These com-
pounds act as antioxidants. They contain several double bonds, 
which react with reactive oxygen species (ROS) to scavenge radi-
cals. While carotenes are composed of only carbon and hydrogen, 
xanthophylls include other elements. Lutein is a xanthophyll that is 
a hydroxycarotenoid (C40H56O2) (Fig. 1 ). Lutein’s properties are 
considerably different from those of carotenes.  
  Carotenes are transformed to vitamin A in the body, and are 
therefore called pro-vitamin A [1]. Lutein is a yellow crystal that is 
found in some vegetables, such as kale, spinach, and broccoli, and 
also in the marigold flower, which is used as a source for a supple-
mentary micronutrient. 
  Since animals cannot synthesize lutein, they must obtain it from 
the diet. It is absorbed from the intestinal epithelium into the blood, 
and circulates systemically to reach the liver, lung, and retina [1-3]. 
In the human retina, it is concentrated in the macula, the most cen-
tral region (Fig. 2A, B), so it is called a macular pigment. The 
analysis of stereoisomers of this macular pigment revealed two 
stereoisomeric carotenoids with identical properties to lutein and 
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zeaxanthin [4]. The ratio of these isomers is different in each tissue 
(e.g., between the retina and plasma), suggesting that they are lo-
cally inter-converted. This study further showed that this transfor-
mation [(3R,30R,60R)-lutein  nondietary metabolite (3R,30S-
meso)-zeaxanthin   (3R,30R)-zeaxanthin] occurs metabolically 
through a series of oxidation-reduction and double-bond isomeriza-
tion reactions [1].  
  Lutein exists not only in the macula but also broadly in the 
retina [5]. It is found in the photoreceptor outer segments (OSs), 
where light stimuli are received, and in the retinal pigment epithe-
lium, where OSs are phagocytosed and recycled. However, interest-
ingly, resonance Raman imaging showed that lutein is most abun-
dant in a neuronal network layer connecting the photoreceptor cells 
(the outer nuclear layer; ONL) to the secondary neurons, called the 
outer plexiform layer (OPL) (Fig. 2B) [6]. Because lutein is a yel-
low pigmented crystal, it has long been thought to act as a filter of 
blue light, which has high energy of the visible spectrum. 
2. RESULTS OF CLINICAL STUDIES 
  It has long been known that some phytochemicals can be medi-
cally beneficial. For example, the cardiac drug digitalis was first 
discovered in the leaves of the digitalis flower [7], and the analgesic 
morphine was found in the opium poppy [8]. However, lutein’s 
effects have just started to be evaluated, and only for limited use as 
a preventive therapy of age-related macular degeneration (AMD), a 
vision-threatening disease. 
  After the report of an inverse association between vegeta-
ble/fruit intake and AMD [9], a large clinical study, the Age-related 
Eye Disease Study (AREDS), was performed to examine ways to 
prevent AMD. In its annexed study, participants reporting the high-
est dietary intake of lutein/zeaxanthin were statistically less likely 
to have advanced AMD (either the atrophic or exudative type) or to 
be at high risk of developing it, than those reporting the lowest 
dietary intake [10], suggesting that lutein plays some protective role 
in the eye. Another study showed that, in 90 patients with atrophic 
AMD, lutein intake increased the macular pigment optical density 
(MPOD) and was correlated with an increase in visual contrast 
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those who took a large amount of lutein or zeaxanthin [12] and who 
showed high levels of plasma carotenoid [13,14] but not of other 
antioxidants, vitamin C, E, or selenium [13]. 
  A study using donor eyes showed a negative association be-
tween lutein content in the retina and AMD risk [15]. Retinas from 
56 donors with AMD and 56 controls were analyzed using high-
performance liquid chromatography. The levels of lutein and zeax-
anthin were lower in the AMD retinas in both the central retina 
(62% of control), including the macula, and the peripheral retina 
(70-80% of control). Taken together, these observations indicate 
that lutein obtained from the diet accumulates in the retina and may 
act locally to prevent disease. 
  In a second large-scale clinical study, AREDS2, the effects of 
lutein/zeaxanthin and/or docosahexaenoic/eicosapentaenoic acids in 
approximately 4000 AMD patients are presently being tested for 
their possible use in preventive therapy. This possibility is based on 
the involvement of oxidative stress-related conditions, such as 
smoking and hypertension [16], in the risk for AMD, and the pro-
posed anti-oxidative action of lutein. However, the biological role 
of lutein in the body, including the retina, has not yet been eluci-
dated. The association between arthritis and AMD [16], and be-
tween the genetic abnormality of complement factor and AMD [17-
19], have also been reported, suggesting that inflammation is re-
lated to AMD. However, an anti-inflammatory effect of lutein has 
been hardly documented.  
  The retina is part of the central nervous system, and thus regen-
erates poorly, if at all. Therefore, it is essential to protect the retinal 
neurons from oxidative stress and inflammation. Many adult dis-
eases, including diabetes and AMD, involve oxidative stress and 
inflammation. To investigate lutein’s potential as a preventative 
therapy for these diseases, it is important to study its mechanisms of 
action in vivo.  
3. BIOLOGICAL EFFECTS AND UNDERLYING MOLECU-
LAR MECHANISMS OF LUTEIN IN MOUSE RETINAL 
DISEASE MODELS  
1) Lutein’s Effects on Acute Innate Inflammation of the Retina 
  To simplify the analysis of lutein’s biological actions in vivo, 
we first used an endotoxin-induced uveitis (EIU) mouse model, 
generated by the injection of lipopolysaccaride (LPS) [20]. 
i) Retinal Neuronal Disorder During Inflammation 
  In the EIU model, the innate immune system causes intraocular 
inflammation, which involves the neural retina [20-24]. In human 
uveitis cases, inflammation spreads to the retina as well as the uvea 
and causes visual dysfunction, although the underlying mechanism 
has long been obscure. In the EIU model mice, electroretinogram 
(ERG), an objective method for measuring visual function in both 
humans and mice, shows a decrease in the a-wave amplitude, and 
photoreceptor cell dysfunction [20,21,23,24]. This effect involves a 
reduction in rhodopsin protein, which is localized in the OS of pho-
toreceptor cells and is indispensable for photo-transduction. This 
protein reduction results from excessive protein degradation by the 
ubiquitin-proteasome system (UPS), in which the protein-selective 
E3-ligase, ubiquitin-protein ligase E3 component n-recognin 1 
(Ubr1) [24], is upregulated by STAT3 activation downstream of 
inflammatory signals, such as interleukin-6 (IL-6). The loss of 
rhodopsin shortens the OSs [25] and decreases light reception and 
photoreceptor cell function. Under physiological conditions, sup-
pressor of cytokine signaling 3 (SOCS3), which modulates acti-
vated STAT3 via a feedback loop, fine-tunes this signal [24,26]. 
Once this feedback system is overwhelmed, however, the STAT3 
activation and subsequent rhodopsin reduction are accelerated, 
resulting in vision loss [23,24]. 
 
 
 
 
 
Fig. (1). Chemical structure of lutein. 
C40H56O2. Lutein contains double bonds that scavenge ROS. 
 
 
 
 
 
 
 
 
Fig. (2). The human retina. 
(A) Fundus photograph. An arrow shows the center of the retina, where photoreceptor cells and light stimuli are concentrated. (B) Optical coherence tomogra-
phy (OCT) image showing a cross section of the central part of the retina. NFL, nerve fiber layer; OPL, outer plexiform layer; ONL, outer nuclear layer (pho-
toreceptor cell layer); OS, outer segment. 
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ii) Lutein’s Effect During Inflammation Includes ROS Suppres-
sion 
  The UPS is also accelerated by protein modifications resulting 
from oxidative stress. Therefore, if oxidative stress is involved in 
inflammation and lutein has an anti-oxidative effect in vivo, lutein 
might protect visual function by suppressing inflammation-related 
protein degradation. 
  To test this hypothesis, we pre-treated EIU model mice with 
lutein, and examined whether the rhodopsin protein level, OS 
length, and visual function (photoreceptor cell function) were pre-
served during inflammation [20]. Interestingly, oxidative stress was 
induced in the retina during inflammation, and lipid peroxidation 
was observed in the plasma membrane of the OSs, supporting the 
idea that rhodopsin, a transmembrane protein, was modified by the 
inflammation. These effects were successfully suppressed by lutein 
(Fig. 3), indicating that lutein protects the function of the retinal 
neural tissue by reducing oxidative stress and protein loss. Consis-
tently, lutein preserved a-wave amplitude in ERG, indicating that 
lutein protects visual function during inflammation. 
iii) Lutein Suppresses Inflammatory Signaling 
  Lutein’s effect on rhodopsin preservation is accompanied by a 
suppression of STAT3 activation. STAT3 is generally activated by 
inflammatory cytokines, one of which, IL-6 is regulated by acti-
vated STAT3. Thus, once STAT3 activation exceeds a certain level, 
the IL-6-STAT3 pathway enters a vicious cycle that exacerbates the 
pathological condition. However, lutein suppresses STAT3 activa-
tion, thereby suppressing this vicious cycle, and efficiently prevent-
ing tissue damage. Regarding the mechanism for inhibiting the 
STAT3 activation, the direct pathway of STAT3 phosphorylation 
and activation by ROS 
27 may be suppressed by lutein. Therefore, 
there is a link between oxidative stress and inflammation, which 
can be regulated by lutein; thus, lutein has an anti-inflammatory 
effect (Fig. 4). This scenario is supported by previous reports show-
ing that lutein reduces the intraocular infiltration of inflammatory 
cells in models of EIU [28] and laser-induced choroidal neovascu-
larization [29].  
  STAT3 activation and its related pathological changes in the 
retina of the EIU model are also suppressed by angiotensin II type 1 
receptor (AT1R) blockers [30]. This is not only because AT1R 
blockers suppress STAT3 activation downstream of AT1R, but also 
because they suppress the ROS generation by NADPH oxidase 
downstream of AT1R signaling. 
2) Lutein’s Effects on Diabetic Retinopathy 
  Although chronic neurodegeneration is well known to occur in 
diabetes, there is no established therapy to prevent it. Given that 
diabetes involves oxidative stress, a constant intake of the anti-
oxidant, lutein, might help to prevent this complication in the retina. 
i) Retinal Neurodegeneration in Diabetes 
  In a mouse model of type 1 diabetes induced by injecting strep-
tozotocin (STZ), a compound that is toxic to the insulin-producing 
beta cells of the pancreas, impaired visual function is obvious one 
month after the onset of diabetes [21]. The ERG shows impaired 
oscillatory potentials (OPs), which reflects inner retinal neurode-
generation. This change is also observed in humans from an early 
stage, before diabetes-induced microangiopathy is obvious [31,32]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (3). Lutein’s effect on oxidative stress in the inflamed retina. 
ROS in the retina were detected by dihydroethidium (DHE) (A-D) and BODIPY-C11 which indicates lipid peroxidation (E-K). Lutein administration sup-
presses ROS in the retina. (Sasaki et al. Invest Ophthalmol Vis Sci 2009). 
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The retinal neurodegeneration and visual dysfunction continue to 
progress after microangiopathy has been made quiescent by laser 
treatment or surgical intervention. This neuronal disorder is caused 
by the diabetic and toxic microenvironment.  
  We showed that local AT1R signaling contributes to this retinal 
neurodegeneration [21]. We found that the angiotensin II signal is 
upregulated locally in the retina, and the suppression of neuronal 
damage by AT1R blockers was not associated with a reduction in 
systemic blood glucose levels. Inner retinal layer involves a neu-
ronal synaptic network where primary integration of the visual in-
formation occurs via active neurotransmitter release. Synaptic vesi-
cles are indispensable for this biological activity, and synapto-
physin, a synaptic-vesicle component, plays a key role in various 
neurodegenerative diseases, most likely through synaptic network 
abnormalities; genetically abnormal synaptophysin causes mental 
retardation [33], and abnormal forms of it are found in Alzheimer’s 
disease and Parkinson’s disease [34].  
  We showed that the protein level of synaptophysin is also re-
duced in the diabetic retina through the pro-inflammatory AT1R 
signaling pathway [21] by activating Extracellular Signal-regulated 
Kinase (ERK). ERK can induce seven in absentia (Sina) [35], 
which mammalian homologues, the seven in absentia homologues 
(Siahs), have turned out to be a synaptophysin-selective E3-ligase 
[36]. The involvement of a common pathogenic pathway, i.e., pro-
tein degradation, in the diabetes and EIU models is interesting, and 
consistent with previous findings that diabetic influence in the ret-
ina involves inflammation [21,37] and oxidative stress [38]. Since 
locally activated AT1R signaling can cause oxidative stress, we 
hypothesized that a constant intake of lutein might prevent the reti-
nal neurodegeneration induced by diabetes. 
ii) Lutein Protects Neuronal Function in the Diabetic Retina 
  Strikingly, diabetic mice constantly fed a lutein-supplemented 
diet show preserved visual function as measured by ERG, indicat-
ing the prevention of inner retinal damage [38]. Lutein suppresses 
the generation of ROS in the diabetic retina without changing the 
systemic blood glucose level. 
  In the retina of lutein-fed diabetic mice, ERK activation is sup-
pressed and synaptophysin protein is preserved. Therefore, the 
chronic activation of ERK is also associated with oxidative stress 
and is affected by lutein’s anti-oxidative and anti-inflammatory 
actions, to protect neuronal activity. Moreover, lutein is reported to 
bind to a protein, glutathione-S-transferase 1, in the monkey retina, 
which localizes to the synaptic region, OPL, in addition to the OSs 
of photoreceptor cells [6]. This distribution is consistent with lu-
tein’s protection of retinal neurons. 
 Lutein’s protection of synaptic vesicle protein affects more than 
the synaptic activity. Neuronal activity induces the translocation of 
calcium ions, which needs to be regulated to maintain cellular sur-
vival and induces the expression of a neuronal trophic factor, brain-
derived neurotrophic factor (BDNF) [39,40]. BDNF, whose defi-
ciency is associated with a number of neurodegenerative disorders 
(e.g. Huntington’s disease, Alzheimer’s disease, and Parkinson’s 
disease), is also downregulated in the diabetic retina [38]. Impor-
tantly, however, lutein attenuates this decrease, most likely through 
its protection of synaptic activity (Fig. 4). It has not been deter-
mined whether BDNF can be modified or degraded by oxidative 
stress.  
  It is anticipated that neurodegenerative diseases will be treated 
using strategies designed to increase the BDNF level [40] —the 
administration of recombinant proteins or drugs that activate its 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Model of the underlying mechanisms of lutein’s effect. 
Lutein suppresses oxidative stress in tissue. This suppresses the degradation of functional proteins and DNA damage caused by pro-inflammatory molecules 
induced in the tissue during inflammation or diabetes, or as a result of light exposure, preventing neuronal dysfunction and death. Lutein can absorb and block 
light. 
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endogenous expression and gene therapy to relieve the symptoms of 
Alzheimer’s disease and Parkinson’s disease are now in trial. If the 
BDNF reduction in these neurodegenerative diseases involves a 
mechanism common to that of diabetic retinopathy, lutein admini-
stration might also be considered as a therapeutic strategy for these 
neuronal diseases. 
iii) Lutein Promotes Neuronal Survival in the Diabetic Retina 
  Reductions in the neuronal functional protein synaptophysin 
and in the neurotrophic factor BDNF are implicated in the neuronal 
dysfunction of diabetic model mice, as shown by ERG [38]. These 
changes are already visible in 1 month from the onset of diabetes, 
although the change might be reversible at this time. However, 
diabetic neuronal damage ultimately causes neuronal cell death; 
after 4 months from the onset of diabetes, the numbers of retinal 
ganglion cells and inner retinal cells are clearly reduced [38]. Reti-
nal neurons do not appear to proliferate; thus, this change is irre-
versible. Importantly, lutein protects the retinal ganglion cells and 
inner retinal cells from diabetes-induced cell death for at least 4 
months after diabetes onset. That lutein protects not only neuronal 
function but also supports cell survival in the animal model helps 
explain its effectiveness. Although further studies are required, the 
long-term constant intake of lutein is a potential neuroprotective 
and preventive therapy for diabetic retinopathy. 
3) Lutein’s Effects in Light-induced Retinal Degeneration 
  Lutein has anti-oxidative and anti-inflammatory effects that are 
independent of light stimuli (described above). However, lutein’s 
role in the macula is assumed to be in protecting the macular region 
of the retina from light damage. To investigate the mechanism of 
lutein’s protective effect against light exposure, we used a mouse 
model of light-induced retinal degeneration. In this model, photore-
ceptor cells gradually degenerate and die in two phases: an immedi-
ate phase, and a subsequent, long-lasting phase caused by cumula-
tive changes in enzymatic activities that are triggered by light expo-
sure [41-43]. In this long-lasting phase, double-stranded breaks in 
DNA cause the loss of photoreceptor cells by apoptosis; notably, 
this most severe type of DNA damage is attenuated by lutein pre-
treatment [44] (Fig. 4).  
  The light-induced visual dysfunction measured by ERG in these 
mice is significantly suppressed by lutein administration. ROS in-
duced in the light-exposed retina are also suppressed by lutein. 
Although it is not yet known whether this reduction in oxidative 
stress is caused by the blockage of light or the scavenging of ROS, 
this effect of lutein is significant. Mice do not have a macula, how-
ever, this effect is consistent with the lutein’s broad distribution in 
the whole area of the retina as reported in the human retina (de-
scribed in the section 1 and 2). 
4. SUMMARY 
  Lutein is produced in plants, not mammals, but it is delivered to 
and accumulates in mammalian tissue. Lutein’s biological effects 
have long been noted, but research on its underlying molecular 
mechanisms has just begun. Lutein affects the pathological path-
ways of inflammatory cytokines, such as IL-6 and angiotensin II 
signaling, and prevents neurodegeneration (e.g.,  via the loss of 
function-essential proteins and trophic factors, and via DNA dam-
age) that can be induced by oxidative stress. Lutein protects tissue 
against pathological stimuli regardless of light exposure. Further 
investigations will continue to explore the use of lutein in tissue 
protection, including neuroprotection. 
ABBREVIATIONS 
AMD  =  Age-related macular degeneration; 
AT1R  =  Angiotensin II type 1 receptor; 
BDNF = Brain-derived  neutrophic  factor; 
EIU =  Endotoxin-induced  uveitis; 
ERG =  Electroretinogram; 
ERK  =  Extracellular Signal-regulated Kinase; 
IL =  Interleukin; 
LPS =  Lipopolysaccaride; 
ONL =  Outer  nuclear  layer; 
OPL  =  Outer plexiform layer; 
OSs =  Outer  segments; 
UPS =  Ubiquitin-proteasome  system 
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